EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Contralateral Testicular Biopsy in Men with Testicular Cancer

John Pfail, Ines Santiago, Thomas L Jang, Pia Paffenholz, EAU-YAU Penile and Testis Cancer Working Group

European Urology Focus · 2024-05 · 10 (3) · 370-372

DOI: 10.1016/j.euf.2024.06.006 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift European Urology Focus, 2024-05. Verfasst von John Pfail und 4 weiteren Autor:innen. Beteiligte Einrichtung: Section of Urologic Oncology, Rutgers Cancer Institute and Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA. Hauptthemen laut MEDLINE: Testicular Neoplasms, Neoplasms, Germ Cell and Embryonal, Testis, Carcinoma in Situ. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Testicular germ cell tumors (TGCTs) are an uncommon disease accounting for roughly 1% of newly diagnosed cancers in men worldwide. Incidence rates vary from 7 to 10 per 100000 males in Europe and North America. Approximately 2-5% of patients with unilateral TGCT will also harbor germ cell neoplasia in situ (GCNIS) in the contralateral testicle, which may progress to cancer in at least 50% of individuals. The question of whether routine contralateral testicular biopsy should be performed in patients with testicular cancer to detect the presence of GCNIS remains controversial. Screening and treatment of GCNIS are warranted only if the patient's outcome will be improved and there will be little impact on testicular function. In this review, we evaluate current guideline recommendations and the issues concerning contralateral testicular biopsy. PATIENT SUMMARY: Among men with cancer in one testicle, about 2-5% will also have cells with cancerous potential, called germ cell neoplasia in situ (GCNIS), in the other testicle. This mini-review discusses issues related to routine biopsy of the other testicle and the risk factors and treatment options for GCNIS in men with testicular cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Testicular NeoplasmsNeoplasms, Germ Cell and EmbryonalTestisCarcinoma in SituHumansMaleBiopsyPractice Guidelines as TopicRisk Factors

Stichwörter der Autor:innen

Contralateral testicular biopsyTesticular cancer

Autor:innen und Institutionen

  • Section of Urologic Oncology, Rutgers Cancer Institute and Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA.
  • Department of Urology, Klinikum am Urban, Berlin, Germany.
  • Section of Urologic Oncology, Rutgers Cancer Institute and Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA. Electronic address: jangtl@cinj.rutgers.edu.
  • Department of Urology, Uro-Oncology, Robot Assisted and Reconstructive Urologic Surgery, University of Cologne Faculty of Medicine and University Hospital Cologne, Cologne, Germany; Center for Integrated Oncology Köln-B…

Zitieren

APA

Pfail, J., Santiago, I., Jang, T. L., Paffenholz, P., & EAU-YAU Penile and Testis Cancer Working Group (2024). Contralateral Testicular Biopsy in Men with Testicular Cancer. European Urology Focus, 10(3), 370-372. https://doi.org/10.1016/j.euf.2024.06.006

Vancouver

Pfail J, Santiago I, Jang TL, Paffenholz P, EAU-YAU Penile and Testis Cancer Working Group. Contralateral Testicular Biopsy in Men with Testicular Cancer. European Urology Focus. 2024;10(3):370-372. doi:10.1016/j.euf.2024.06.006

BibTeX
@article{Pfail2024,
  author = {Pfail, John and Santiago, Ines and Jang, Thomas L and Paffenholz, Pia and EAU-YAU Penile and Testis Cancer Working Group, EAU-YAU Penile and Testis Cancer Working Group},
  title = {Contralateral Testicular Biopsy in Men with Testicular Cancer},
  journal = {European Urology Focus},
  year = {2024},
  volume = {10},
  number = {3},
  pages = {370--372},
  doi = {10.1016/j.euf.2024.06.006}
}
Kostenlos starten →